IDEXX Laboratories was featured in an October 23 headline ahead of its Q3 earnings report. The headline does not include earnings estimates or company guidance.
The October 23 EOD headline, “Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings,” puts the upcoming report in focus. The supplied information does not give a report date, expected results, or new guidance, so the headline alone does not indicate what IDEXX will report.
Investor takeaway: Q3 earnings are the event to watch, but the supplied catalyst offers no specific expectations or new company disclosures.
Advertisement
IDEXX Laboratories Inc
IDXX.US
IDXX.US
IDEXX Laboratories Inc
WealthAwesomeMarket cap
$44.15B
P/E
39.4x
52W high
$769.98
52W low
$500.61
1W change
+0.00%
Beta
1.55
Analyst Price Targets
Based on 14 analysts covering IDXX · as of Oct 26, 2026
Wall Street analysts forecast IDXX stock price to rise 24.6% over the next 12 months.
Consensus
Buy3.93 / 5.00
Avg. Target
C$698.00
+24.6% Upside
Current Price
C$560.38
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IDXX's historical volatility
30-Day Vol
22.7%
Annualized
90-Day Vol
28.0%
Annualized
Trend (90d)
+1.2%
Annualized drift
90d Mean
C$562.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$561.17 | C$518.91 – C$606.87 |
| 60 trading days | C$561.96 | C$503.06 – C$627.76 |
| 90 trading days | C$562.76 | C$491.39 – C$644.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
IDEXX closed at US$560.65 ahead of the Q3 earnings headline
The closing price was 5.2% above the 50-day moving average of US$533.01 and 2.7% below the 200-day average of US$576.39.
Bull case
The supplied figures show a 25.0% profit margin and trailing-twelve-month EPS of US$14.23. These provide financial context ahead of the report, but do not indicate what Q3 results will be.
Bear case
IDEXX shares were 2.7% below the 200-day moving average. The catalyst also provides no Q3 estimates or guidance to clarify expectations for the report.
The Q3 earnings preview is the catalyst
The October 23 EOD headline, “Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings,” is the event in focus. The supplied facts do not say when the company will report, what analysts expect, or whether IDEXX has issued new guidance. A separate October 22 headline mentions raised guidance and product expansion, but no details are provided, so those claims cannot be assessed here. For company background, see the IDEXX Laboratories stock page.
Advertisement
Shares were US$560.65 at the latest close
IDEXX’s latest close was US$560.65. The supplied figures show a 1.13% decline over one day, no change over one week, a 7.35% gain over one month, and a 16.36% decline year to date. The close was 5.2% above the 50-day moving average of US$533.01 and 2.7% below the 200-day average of US$576.39.
The reported 52-week range was US$500.61 to US$769.98, with the share price at 22% of that range. Latest volume was 3,714 shares, compared with a 20-day average of 514,634, or 0.77 times that average. These figures describe the supplied market snapshot; they do not explain what to expect from earnings.
What to watch in the report
The next key information will come from the Q3 report and any guidance the company provides. The supplied catalyst includes neither the reporting date nor expected results. IDEXX’s trailing-twelve-month EPS was US$14.23, its P/E was 39.3802, its profit margin was 25.0%, and its return on equity was 74.2%. Its reported market capitalization was US$44,147,363,840. Investors following IDXX.US can use the IDEXX Laboratories company page for stock information, while keeping these background figures separate from any new Q3 disclosures.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
